A common question among Indian’s nowadays, who will get the COVID-19 vaccine in India first? But now the national expert group on COVID vaccine administration met for the first time on Wednesday. This comes into light via Mint’s recent report.
As per the report, grom selection to the procurement of the COVID vaccine, the committee deliberated on principles for prioritisation of population groups for vaccination. Mainly Dr. V K Paul (Member, Niti Aayog) and Secretary (Ministry of Health and Family Welfare) have co-chaired the meeting.
3 COVID-19 Vaccine Candidates Enters Final Stage
Notably, three vaccine candidates are in different stages of human clinical trials in India. Among these, first is the Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing the Oxford vaccine in India.
The Serum Institute of India has also permitted for conducting Phase 2 and Phase 3 human clinical trials. Would like to inform you that this vaccine is developed by Oxford University.
Bharat Biotech, the second candidate is working on a collaboration with the ICMR (Indian Council of Medical Research. And the third one is Zydus Cadila Ltd. These two are also in phase-1 and phase-2 human clinical trial stages for their vaccines.
Interestingly, as reported by Mint, the expert group on COVID vaccine administration also considering the main issue. Yes! here we are talking about the creation of a digital infrastructure for inventory management and delivery mechanism of the vaccines. They also deliberated on the tracking of the vaccination process with particular focus on last-mile delivery.
Reportedly, the government said in its statement;
“They discussed on broad parameters guiding the selection of COVID-19 vaccine candidates for the country and sought inputs from Standing Technical Sub-Committee of National Technical Advisory Group on Immunization (NTAGI).”
“The group delved on the procurement mechanisms for COVID-19 vaccine, including both indigenous and international manufacturing along with guiding principles for prioritization of population groups for vaccination.”
Procurement Of COVID Vaccine In India
Reportedly, the committee advised states not to chart separate pathways of the procurement of the COVID vaccine. The experts were also taken up the issues related to the financial resources required for procurement, safety, and surveillance.
India will leverage domestic vaccine manufacturing capacity and will also engage with all international players, the expert group discussed. Reportedly, India will also look after low and middle-income countries
Clearly, this meeting comes in the backdrop of Russia as on Tuesday the country claimed to developed the world’s first coronavirus vaccine. But scientists and some people familiar with the matter have questioned the approval of the vaccine since it still said to be in Phase 3 trial.